Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7466513rdf:typepubmed:Citationlld:pubmed
pubmed-article:7466513lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:7466513lifeskim:mentionsumls-concept:C0152018lld:lifeskim
pubmed-article:7466513lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:7466513lifeskim:mentionsumls-concept:C0596873lld:lifeskim
pubmed-article:7466513lifeskim:mentionsumls-concept:C0439859lld:lifeskim
pubmed-article:7466513lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:7466513pubmed:issue6lld:pubmed
pubmed-article:7466513pubmed:dateCreated1981-4-21lld:pubmed
pubmed-article:7466513pubmed:abstractTextThe reactivity of lymphocytes from patients with oesophageal carcinoma in response to mitogenic stimulation with phytohaemagglutinin was assessed in four culture systems in an attempt to demonstrate an inhibitory effect of cancer serum on lymphocyte transformation. The metaphase index (number of cells at metaphase/1000 live cells) was used to determine lymphocyte reactivity of patients and controls in the presence of: (a) autologous plasma; (b) pooled AB serum; (c) pooled plasma from patients with oesophageal cancer, and (d) fetal calf serum. The division of lymphocytes from cancer patients was significantly depressed in the presence of autologous plasma (p<0,001) when compared with division of lymphocytes of control subjects. No significant difference was evident in pooled AB serum, homologous cancer plasma or fetal calf serum. The depressed lymphocyte reactivity in cancer patients appears to be related to a serum inhibitory factor.lld:pubmed
pubmed-article:7466513pubmed:languageenglld:pubmed
pubmed-article:7466513pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7466513pubmed:citationSubsetIMlld:pubmed
pubmed-article:7466513pubmed:statusMEDLINElld:pubmed
pubmed-article:7466513pubmed:monthFeblld:pubmed
pubmed-article:7466513pubmed:issn0256-9574lld:pubmed
pubmed-article:7466513pubmed:authorpubmed-author:AngornI BIBlld:pubmed
pubmed-article:7466513pubmed:authorpubmed-author:HaffejeeA AAAlld:pubmed
pubmed-article:7466513pubmed:authorpubmed-author:RobinsonK MKMlld:pubmed
pubmed-article:7466513pubmed:issnTypePrintlld:pubmed
pubmed-article:7466513pubmed:day7lld:pubmed
pubmed-article:7466513pubmed:volume59lld:pubmed
pubmed-article:7466513pubmed:ownerNLMlld:pubmed
pubmed-article:7466513pubmed:authorsCompleteYlld:pubmed
pubmed-article:7466513pubmed:pagination187-9lld:pubmed
pubmed-article:7466513pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7466513pubmed:meshHeadingpubmed-meshheading:7466513-...lld:pubmed
pubmed-article:7466513pubmed:meshHeadingpubmed-meshheading:7466513-...lld:pubmed
pubmed-article:7466513pubmed:meshHeadingpubmed-meshheading:7466513-...lld:pubmed
pubmed-article:7466513pubmed:meshHeadingpubmed-meshheading:7466513-...lld:pubmed
pubmed-article:7466513pubmed:year1981lld:pubmed
pubmed-article:7466513pubmed:articleTitleInhibition of mitogen-induced lymphocyte proliferation by autologous serum in oesophageal carcinoma.lld:pubmed
pubmed-article:7466513pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7466513pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:7466513pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed